Literature DB >> 17150163

Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion.

Qiana L Matthews1, Don A Sibley, Hongju Wu, Jing Li, Mariam A Stoff-Khalili, Reinhard Waehler, J Michael Mathis, David T Curiel.   

Abstract

An advantage of the adenoviral vector is its molecular flexibility, which allows for vector tropism modifications for the purpose of cell targeting. In addition to targeting ligands, the capacity to incorporate heterologous peptides has allowed capsid incorporation of other functionalities. We have defined the minor capsid protein IX (pIX) as a locus capable of presenting incorporated ligands on the virion surface. Thus, we sought to exploit the possibility of incorporating functional proteins at pIX. In our current study, we sought to expand the potential utility of our capsid labeling strategy by developing simultaneous imaging capacity for dedicated small animal positron emission tomography and bioluminescence imaging on a single adenoviral vector. Therefore, we constructed an adenovirus that incorporates a fusion protein of herpes simplex virus type 1 thymidine kinase and firefly luciferase (Luc) (TK-Luc) into adenovirus capsid pIX. Our study herein clearly demonstrates our ability to rescue viable adenoviral particles that display functional TK-Luc as a component of their capsid surface. Most importantly, Ad-pIX-TK-Luc retained dual enzymatic functions in vitro and in vivo. This dual-modality approach will allow dynamic or real-time imaging analysis of adenovirus-based interventions with maximized analytic flexibility and enhanced resolution potential.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17150163      PMCID: PMC1781529     

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  32 in total

1.  Noninvasive imaging of protein-protein interactions in living animals.

Authors:  Gary D Luker; Vijay Sharma; Christina M Pica; Julie L Dahlheimer; Wei Li; Joseph Ochesky; Christine E Ryan; Helen Piwnica-Worms; David Piwnica-Worms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

Review 2.  Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors.

Authors:  M G Rots; D T Curiel; W R Gerritsen; H J Haisma
Journal:  J Control Release       Date:  2003-02-21       Impact factor: 9.776

Review 3.  Non-invasive imaging of reporter genes.

Authors:  Harvey R Herschman
Journal:  J Cell Biochem Suppl       Date:  2002

Review 4.  Adenoviral vectors for gene transfer and therapy.

Authors:  Christoph Volpers; Stefan Kochanek
Journal:  J Gene Med       Date:  2004-02       Impact factor: 4.565

5.  Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion.

Authors:  Jing Li; Long Le; Don A Sibley; J Michael Mathis; David T Curiel
Journal:  Virology       Date:  2005-08-01       Impact factor: 3.616

6.  Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas.

Authors:  A Jacobs; J Voges; R Reszka; M Lercher; A Gossmann; L Kracht; C Kaestle; R Wagner; K Wienhard; W D Heiss
Journal:  Lancet       Date:  2001-09-01       Impact factor: 79.321

7.  Optical imaging of cardiac reporter gene expression in living rats.

Authors:  Joseph C Wu; Masayuki Inubushi; Gobalakrishnan Sundaresan; Heinrich R Schelbert; Sanjiv S Gambhir
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

8.  Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model.

Authors:  Mian M Alauddin; Atranik Shahinian; Erlinda M Gordon; Peter S Conti
Journal:  Mol Imaging       Date:  2004-04       Impact factor: 4.488

9.  Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors.

Authors:  F J Fallaux; O Kranenburg; S J Cramer; A Houweling; H Van Ormondt; R C Hoeben; A J Van Der Eb
Journal:  Hum Gene Ther       Date:  1996-01-20       Impact factor: 5.695

10.  Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX.

Authors:  Jort Vellinga; Martijn J W E Rabelink; Steve J Cramer; Diana J M van den Wollenberg; Hans Van der Meulen; Keith N Leppard; Frits J Fallaux; Rob C Hoeben
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more
  31 in total

1.  Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Zachary C Hartman; Nathaniel J Schuldt; Jeannine Scott; Sarah Godbehere; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

2.  Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.

Authors:  Lena J Gamble; Hideyo Ugai; Minghui Wang; Anton V Borovjagin; Qiana L Matthews
Journal:  J Mol Biochem       Date:  2012-02-15

3.  Fusion of Large Polypeptides to Human Adenovirus Type 5 Capsid Protein IX Can Compromise Virion Stability and DNA Packaging Capacity.

Authors:  Kathy L Poulin; Emily R McFall; Grace Chan; Natacha B Provost; Carin Christou; Adam C Smith; Robin J Parks
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

4.  Noninvasive bioluminescence imaging in small animals.

Authors:  Kurt R Zinn; Tandra R Chaudhuri; April Adams Szafran; Darrell O'Quinn; Casey Weaver; Kari Dugger; Dale Lamar; Robert A Kesterson; Xiangdong Wang; Stuart J Frank
Journal:  ILAR J       Date:  2008

Review 5.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

Review 6.  Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.

Authors:  Qiana L Matthews
Journal:  Mol Pharm       Date:  2010-12-01       Impact factor: 4.939

7.  Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Authors:  Wibke Bayer; Matthias Tenbusch; Ruth Lietz; Lena Johrden; Simone Schimmer; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

8.  Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals.

Authors:  A Asokan; J S Johnson; C Li; R J Samulski
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

9.  Derivation of a triple mosaic adenovirus for cancer gene therapy.

Authors:  Yizhe Tang; Hongju Wu; Hideyo Ugai; Qiana L Matthews; David T Curiel
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

10.  Evaluation of adenovirus capsid labeling versus transgene expression.

Authors:  Jing Li; Aiman Fatima; Svetlana Komarova; Hideyo Ugai; Priyanka Uprety; Justin C Roth; Minghui Wang; Robert A Oster; David T Curiel; Qiana L Matthews
Journal:  Virol J       Date:  2010-01-26       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.